Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Nanoparticulate imatinib mesylate formulations

An imatinib mesylate, nanoparticle technology, applied in nanotechnology, nanotechnology, nanomedicine, etc., can solve the problems of limited treatment results, limited bioavailability, etc., and achieve small doses, increased bioavailability, The effect of increasing the dissolution rate

Inactive Publication Date: 2008-07-30
ELAN PHRMA INT LTD
View PDF57 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, the bioavailability of imatinib mesylate is limited in the fasted state compared to the fed state, which limits the therapeutic outcome of all treatments requiring imatinib mesylate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanoparticulate imatinib mesylate formulations
  • Nanoparticulate imatinib mesylate formulations
  • Nanoparticulate imatinib mesylate formulations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0164] The purpose of this example is to prepare a composition comprising nanoparticulate imatinib mesylate or a salt or derivative thereof.

[0165] 5% (w / w) imatinib mesylate mixed with one or more surface stabilizers such as hydroxypropyl cellulose (HPC-SL) and dioctyl sulfosuccinate (DOSS) can be Aqueous dispersion, and 500 micron PolyMill  Grinding media (Dow Chemical Co.) (e.g. at 89% media loading) in NanoMill  Mill in a 10 ml chamber of 0.01 (NanoMill Systems, King of Prussia, PA; see eg US Pat. No. 6,431,478). In an exemplary method, the mixture may be milled at 2500 rpm for 60 minutes.

[0166] After grinding, the particle size of the ground imatinib mesylate particles can be measured with a Horiba LA 910 particle size analyzer in deionized distilled water. For a successful composition, the initial mean and / or D50 ground imatinib mesylate particle size is expected to be less than 2000 nm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to a nanoparticulate compositions of imatinib mesylate, or a salt or derivative thereof, having improved pharmacokinetic profiles and reduced fed / fasted variability. The nanoparticulate imatinib mesylate particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors and related diseases.

Description

[0001] Cross References to Related Patent Applications [0002] This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 60 / 687,146, filed June 3, 2005, which is hereby incorporated by reference in its entirety. field of invention [0003] The present invention generally relates to compounds and compositions useful in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and related diseases. More specifically, the present invention relates to nanoparticulate imatinib mesylate compositions. The effective average particle size of the nanoparticulate imatinib mesylate composition is less than about 2000 nm. Background of the invention [0004] A. Background on imatinib mesylate [0005] Imatinib mesylate, chemically known as 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl) )-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate, the molecular formula is C 29 h 31 N 7 O·CH 4 SO 3 , ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/14A61K31/506
CPCA61K9/145A61K9/146A61K31/506A61P1/04A61P35/00A61P35/02A61P35/04A61K9/16A61K9/14B82Y5/00
Inventor S·詹金斯G·G·利弗西奇
Owner ELAN PHRMA INT LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com